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The fact that mecamylamine is a secondary amine with “nicotinic” blocking 
properties suggested it would act at the Golgi recurrent collateral-Renshaw-cell 
synapse in the spinal cord. Glass micropipettes were used to obtain extracellu- 
lar Renshaw-cell discharges due to antidromic ventral root stimulation in cats 
anesthetized with pentobarbital. The effects of mecamylamine, hexamethonium, 
physostigmine, and nicotine given intravenously were determined in this prepara- 
tion. It was found that mecamylamine reduced the terminal portions of the 
repetitive discharge of Renshaw cells to antidromic stimulation. The stimulant 
effect of physostigmine and nicotine on Renshaw cells was blocked by mecamy- 
lamine. Hexamethonium in similarly effective ganglionic blocking doses had no 
effect. 
Introduction 
Mecamylamine is unique among ganglionic blocking agents in that it 
is a secondary amine (8, 9, 10). On the basis of its side effects, which 
include central nervous system symptoms, it appears to penetrate the 
blood-brain barrier more easily than ganglionic blocking agents like hexa- 
methonium, which contain quaternary nitrogen atoms. Mecamylamine is 
a more effective antagonist of nicotine than hexamethonium (10). 
Eccles and his associates have shown that the Golgi recurrent collateral 
on the Renshaw inhibitory neuron in the spinal cord behaves pharma- 
cologically like a “nicotinic”-type cholinergic synapse ( 1, 2, 3, 4, 5). The 
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fact that mecamylamine is a secondary amine with nicotinic blocking 
properties suggested that it would easily penetrate the blood-brain barrier 
and exert an action at this synapse. This hypothesis was confirmed ex- 
perimentally. The results obtained constitute the basis of this report. 
Methods 
Twenty-one adult cats of both sexes were used. They were anesthetized 
with pentobarbital given intraperitoneally in a dose of 25 mg/kg. Additional 
doses of 10 mg/kg were given periodically to maintain light general anesthe- 
sia. After rigid fixation of the cat in an appropriate supporting frame, the 
spinal cord was exposed surgically from L4 to L7. The dorsal roots were sec- 
tioned usually at the level of L6 to L7. The ventral roots of these segments 
were cut distally. The proximal stumps were prepared for electrical stimula- 
tion. The spinal cord was transected at TlO in order to eliminate the influ- 
ences of higher centers and to prevent spontaneous movements of the lower 
half of the body. A glass micropipette of approximately 5 u at its tip filled 
with 3 M KC1 was passed from the dorsolateral to ventromedial portion 
of the spinal cord into the Renshaw-cell interneuron pool. After patient 
searching, extracellular potentials were obtained following antidromic 
stimulation of the ventral root. The parameters of electrical stimulation 
were square-wave pulses of O.l-msec duration, of 1 to 10 volts, repeated 
every 5 sec. The electrical activity of the Renshaw cells was recorded 
with an appropriate cathode follower connected to an amplifier. The 
signals were displayed on a dual-beam cathode-ray oscilloscope and re- 
corded photographically by means of a camera. All drugs were adminis- 
tered intravenously. The dosage was calculated on the basis of the salt. 
Results 
Following antidromic stimulation of the ventral roots, Renshaw-cell 
discharges were recorded extracellularly for variable periods of time. With 
excellent preparations it was possible to record from an individual Ren- 
shaw cell for periods longer than 4.5 min. Usually after 30 min Renshaw- 
cell activity seemed to deteriorate. Minimal to no spontaneous activity 
was observed. The principal effect of mecamylamine was to decrease the 
terminal discharges of the Renshaw cell to antidromic stimulation. In 
Fig. 1, panel A, is illustrated a representative record of the normal Ren- 
shaw-cell activity to antidromic stimulation of the ventral root. As has 
been described previously by many others, the Renshaw cell shows initial 
fast-frequency discharges which gradually diminish with time. In ap- 
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proximately 5 min after the intravenous administration of .mecamylamine 
in a dose of 0.5 mg/kg, the frequency of the terminal Renshaw-cell ac- 
tivity was reduced (Fig. 1, panel B). Increasing doses of mecamylamine 
progressively decreased the terminal phases of the repetitive firing of the 
Renshaw cell. As can be seen in panel C, an additional 1.0 mg/kg of 
mecamylamine given intravenously reduced further the terminal activity. 
FIG. 1. Effect of mecamylamine on Renshaw-cell activity. A, control activity 
elicited by antidromic stimulation of ventral roots L6 and Lt. Parameters of stimu- 
lation were square wave pulses of 0.1 msec duration, 3 volts, every 5 sec. B, 6 min 
after mecamylamine 0.5 mg/kg given intravenously. C, 14 min after an additional 
l.Omg/kg of mecamylamine given intravenously. D, 5 min after additional 1.0 
mg/kg of mecamylamine given intravenously. E, 27 min later. Voltage calibration 
and time base shown apply for all panels. 
This effect was even more enhanced after an additional 1.0 mg/kg of 
mecamylamine, as illustrated in panel D. In panel E, is illustrated the 
Renshaw-cell activity approximately 30 min after the administration of 
mecamylamine in an accumulative dose of 2.5 mg/kg. Similar effects were 
observed in ten different animals. Recovery from mecamylamine was not 
obtained in view of the fact that Renshaw-cell activity seldom could be 
recorded for periods beyond 45 min to 1 hour. 
An elaborate statistical analysis of the effects of mecamylamine were 
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not undertaken. However, in the interest of quantification of the results 
the pooled number of Renshaw-cell discharges per five photographic 
frames following antidromic stimulation of the ventral roots of four cats 
were counted before and 10 to 15 min after mecamylamine given in a dose 
of 1.0 mg/kg. The duration of the oscilloscope sweep was approximately 
50 msec. During this time interval before mecamylamine the mean +- S.E. 
of the number of Renshaw-cell discharges was 14.9 2 0.82. After mecamy- 
CAT II 
FIG. 2. Effects of physostigmine and mecamylamine on Renshaw-cell activity. 
A, control activity following antidromic stimulation. Same parameters of stimula- 
tion as in the previous figure except the voltage for antidromic stimulation was 5 
volts. B, 3 min after 300 kg/kg of physostigmine given intravenously. C, 10min 
after 0.5 mg/kg of mecamylamine given intravenously. D, 8 min after a second dose 
of 1.0 mg/kg of mecamylamine given intravenously. 
lamine it was 8.9 f 0.42. This reduction was statistically significant with 
a P value of < 0.001, as determined by the paired comparison student “t” 
test. It is to be noted that mecamylamine only reduced the mean number 
of discharges and did not completely block them. 
Not only could mecamylamine alone reduce the activity of Renshaw 
cells that were fired antidromically, but it could also block the action 
of physostigmine. In panel A of Fig. 2, is shown the control Renshaw-cell 
activity from antidromic stimulation of a ventral root. Three minutes 
after the administration of physostigmine, in a dose of 300 rig/kg given 
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intravenously, Renshaw-cell activity was markedly prolonged, as illustrated 
in panel B, Fig. 2. After the administration of 0.5 mg/kg of mecamyla- 
mine, this enhanced activity was reduced toward control levels (panel C, 
Fig. 2). The addition of another 1.0 mg/kg of mecamylamine even fur- 
ther reduced this activity. After an additional dose of 1.0 mg/kg the 
activity of the Renshaw cells was decreased over control levels in a manner 
similar to those preparations that had no physostigmine. Similar effects 
could be observed in six animals. 
FIG. 3. Effects of nicotine and mecamylamine on spontaneous Renshaw-cell 
activity. A, no spontaneous discharges were observed during the control period 
shown. B, 2 min after 20pg/kg of nicotine given intravenously. C, 1.5 set after 
l.Omg/kg of mecamylamine given intravenously. D, 30sec later. E, 1 min after 
the intravenous administration of mecamylamine. Note the rapid onset of mecamyla- 
mine against the discharges elicited by nicotine as compared to its slower onset of 
action on antidromically evoked Renshaw-cell activity. 
As described previously in pentobarbital-anesthetized animals, norm- 
ally minimal to no spontaneous Renshaw-cell discharges were observed. 
After the administration either of physostigmine, and especially of nico- 
tine, spontaneous cell discharge was clearly increased. Nicotine in doses 
of 20 pg/kg given intravenously was extremely effective in increasing 
the spontaneous discharge. As can be seen in Fig. 3, panel A, no 
spontaneous discharges were seen in this particular portion of the record. 
Within 2 min after the administration of nicotine marked spontaneous 
Renshaw-cell activity was observed (Fig. 3, panel B) even though there 
was no antidromic stimulation of the ventral root. Mecamylamine in 
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doses of 1 mg/kg was very effective in reducing this spontaneous dis- 
charge, as illustrated in panels C, D, and E. This effect of mecamylamine 
occurred within a minute and was therefore much quicker in onset than 
that ordinarily observed on the effects of antidromic stimulation upon 
the Renshaw cells. 
The effects of hexamethonium in doses of 5 to 10 mg/kg given in- 
travenously were determined on Renshaw-cell activity elicited by anti- 
dromic stimulation of the ventral root. In six animals hexamethonium had 
no effect on Renshaw-cell activity. 
Discussion 
Perhaps the best evidence of neurohumoral transmission in the central 
nervous system is that involving the Golgi recurrent collaterals of spinal 
motoneurons synapsing on Renshaw inhibitory interneurons. The in- 
vestigations of Eccles and his colleagues (1, 2, 3, 4, 5) showed that trans- 
mission across this synapse is probably mediated by acetylcholine. The 
intraarterial administration of anticholinesterases, like physostigmine 
and TEPP, caused a marked prolongation of the firing of Renshaw inhibi- 
tory interneurons. On the other hand dihydro$-erythroidine depressed 
transmission across this synapse. Atropine was much less effective in this 
regard. In general substances with a quaternary nitrogen were relatively 
ineffective. Thus, transmission was not affected by either d-tubocurarine 
or neostigmine. However, acetylcholine itself, in large doses intraarterially, 
did stimulate Renshaw cells but there was considerable variability. 
Subsequently these investigators (1, 2, 3, 5) showed that the intra- 
arterial administration of nicotine stimulated Renshaw cells more effec- 
tively than acetylcholine, whereas acetyl-/3-methylcholine, carbaminocho- 
line, arecoline, and succinylcholine were ineffective. On the basis of the 
responses to various agents it appears logical to conclude that this is 
essentially a cholinergic “nicotinic”-type synapse. Studies of this synapse 
are complicated because of the existence of a blood-brain barrier which 
decreases the penetrability of compounds with a positive charge. However, 
the somewhat anomalous effects of drugs on this synapse cannot be wholly 
explained on the basis of a blood-brain barrier. More recently, Curtis and 
Eccles (1, 2) have offered evidence of another diffusional barrier sur- 
rounding the terminals of the motor axon collateral on the Renshaw cell. 
They called this the synaptic barrier. Evidence for such a barrier was 
obtained by means of a five-barreled micropipette for the electrophoretic 
injection of drugs directly in the vicinity of the Renshaw cell. Both 
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acetylcholine and nicotine were very effective in stimulating Renshaw 
cells when applied locally. Acetyl-@methylcholine, carbaminocholine, 
arecoline, and succinylcholine were not very effective when applied elec- 
trophoretically. At most a low-frequency discharge of Renshaw cells was 
produced. Neostigmine and edrophonium locally applied markedly accen- 
tuated the action of acetylcholine. When applied locally, d-tubocurarine 
was relatively ineffective in depressing the responses due to electro- 
phoretically injected acetylcholine or that due to antidromic stimulation 
of the ventral roots. Decamethonium injected locally had little effect on 
Renshaw activity due to antidromic stimulation of the ventral root, but 
prolonged slightly the effects of locally applied acetylcholine. Electro- 
phoretic injection of dihydro-P-erythroidine was effective in reducing the 
activity of Renshaw cells as it was following intraarterial administration. 
Mecamylamine appears to be as effective as dihydro-P-erythroidine 
(4, 7) in reducing Renshaw-cell discharge. This experimental conclusion 
would be expected in view of the fact that the Renshaw cell-Golgi re- 
current collateral synapse appears to be of the “nicotinic” cholinergic 
type. This effect of mecamylamine occurs in doses that produce gangli- 
onic blockade. On the other hand, hexamethonium in doses considerably 
above those producing ganglionic blockade had no effect upon the Ren- 
shaw-cell activity. Therefore, the effects of mecamylamine cannot be 
the result of hypotension. Although in massive doses hexamethonium can 
penetrate the blood-brain barrier of rats (6)) in the doses used in this 
study in cats it had no action on this inhibitory spinal cord synapse. This 
could be related either to failure to penetrate or no appreciable pharma- 
cological action at this spinal cord site. It would appear that the failure 
to penetrate is probably the more important factor. 
It is of considerable interest that mecamylamine has central nervous 
system side effects, such as tremor and mental aberrations including 
delusions or hallucinations, in addition to those characteristic of peripheral 
ganglionic blockade. Since central nervous system side effects are much 
less common, apparently the central actions of this compound are minimal 
compared to its peripheral effects. Although the present study would 
tend to suggest that respectable peripheral ganglionic blocking doses have 
a detectable action on Renshaw-cell terminal discharge, it may very well 
be that this does not interfere markedly with the normal physiological 
inhibition of anterior horn cells. Perhaps for this reason no appreciable 
central manifestations are noted with mecamylamine in therapeutically 
effective doses in man. 
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The effectiveness of mecamylamine to depress the Golgi collateral- 
Renshaw-cell synapse is additional pharmacological evidence that this is 
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